IKNA

Ikena Oncology, Inc. [IKNA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

IKNA Stock Summary

In the News

IKNA Financial details

Company Rating
-
Market Cap
64.18M
Income
-66.87M
Revenue
9.16M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
43
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-1.4
Forward P/E
-
PEG
1.12
P/S
6.74
P/B
0.55
P/C
-
P/FCF
-1.24
Quick Ratio
10.22
Current Ratio
10.41
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.61
EPS next Y
-
EPS next Q
-
EPS this Y
-11.41%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
28.24%
Revenue last 5Y
-7.81%
Revenue Q/Q
-44.39%
EPS Q/Q
2.5%
-
-
-
-
SMA20
-2.57%
SMA50
16.3%
SMA100
-3.4%
Inst Own
-
Inst Trans
-
ROA
-28%
ROE
-41%
ROC
-0.35%
Gross Margin
100%
Oper. Margin
-492%
Profit Margin
-433%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.02-7.64
52W High
+145.14%
52W Low
+1616%
RSI
59.83
Rel Volume
1.07
Avg Volume
429.16K
Volume
457.26K
Perf Week
10.85%
Perf Month
2.14%
Perf Quarter
-
Perf Half Y
-3.38%
-
-
-
-
Beta
0.332
-
-
Volatility
0.83%, 0.54%
Prev Close
4.38%
Price
17.16
Change
6.72%

Something similar

Top by Market Cap
MSFT
VOO
TSLA
CMC.DE
NVD.DE
Same Sector
OPTN
TBPH
ALKS
GBIO
EPRX.TO
Same Price Range
1725.TW
DMB
YYY
FZAJX
002253.SZ
Similar Market Cap
PCCT
POLB.L
0657.HK
MIGIX
AGMH

Company Profile

Healthcare Biotechnology
  • Volume Average 429.16K
  • Market Capitalization 64.18M
  • Employee 43
  • CEO Dr. Mark Manfredi Ph.D.
  • Headquarters Boston,MA,US
  • IPO Date 2021-03-26
  • Website https://ikenaoncology.com

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.